GSK plc 6-K, filed Sep 22, 2022
GSK plc (GSK)
6-K
2022-09-22
For: 2022-09-22
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on September 22, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 22 September 2022, London UK
Oncologic Drugs Advisory Committee to
review Zejula overall survival data from the NOVA phase
III trial in recurrent ovarian cancer
GSK plc (LSE/NYSE: GSK) today announced that the
US Food and Drug Administration (FDA) will convene a meeting of the
Oncologic Drugs Advisory Committee (ODAC) to discuss overall
survival (OS) data from the ENGOT-OV16/NOVA
phase III clinical trial. NOVA
is a randomised, double-blind, placebo-controlled phase III trial
of Zejula (niraparib), an
oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor for
the maintenance treatment of
women with platinum-sensitive recurrent ovarian
cancer.
The phase III NOVA trial met the primary
endpoint of progression-free survival (PFS) in both the gBRCAm and non-gBRCAm cohorts,
demonstrating a statistically significant and clinically meaningful
treatment effect of Zejula in this patient population, regardless of
biomarker status. These PFS results served as the primary basis for
the US FDA approval for the maintenance
treatment of women with recurrent epithelial ovarian, fallopian
tube, or primary peritoneal cancer who are in complete or partial
response to platinum-based chemotherapy. Overall survival was a secondary endpoint.
Updated final overall survival data was recently shared with the
FDA.
Hesham Abdullah, SVP, Global Head of Oncology Development, GSK
said: "We believe
PARP inhibitors, including Zejula,
are important options for the maintenance treatment of patients
with recurrent ovarian cancer, across all biomarker subgroups, who
are in complete or partial response to platinum-based chemotherapy.
We look forward to continuing our ongoing discussions with the
FDA."
The ODAC meeting is scheduled for 22 November
2022. This
is not related to the niraparib indication in
the maintenance
treatment of adult patients with advanced epithelial ovarian,
fallopian tube, or primary peritoneal cancer who are in a complete
or partial response to first-line platinum-based
chemotherapy.
About ovarian cancer
Ovarian cancer is the eighth most common cancer in women
worldwide.[i] Despite
high response rates to platinum-based chemotherapy in the
front-line setting, approximately 85% of patients will experience
disease recurrence.
[ii]
Once the disease recurs, it is rarely curable, with decreasing time
intervals to each subsequent recurrence.
About Zejula (niraparib)
Zejula is an oral, once-daily PARP
inhibitor currently being evaluated in multiple pivotal trials. GSK
is building a robust clinical development programme by assessing
activity across multiple tumour types and evaluating several
potential combinations of Zejula with
other therapeutics. The ongoing development programme includes
several combination studies.
ZEJULA is indicated:
● for
the maintenance treatment of adult patients with advanced
epithelial ovarian, fallopian tube, or primary peritoneal cancer
who are in a complete or partial response to first-line
platinum-based chemotherapy
● for
the maintenance treatment of adult patients with recurrent
epithelial ovarian, fallopian tube, or primary peritoneal cancer
who are in a complete or partial response to platinum-based
chemotherapy
Important Safety Information for ZEJULA
Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML),
including some fatal cases, was reported in 15 patients (0.8%) out
of 1785 patients treated with ZEJULA monotherapy in clinical
trials. The duration of therapy in patients who developed secondary
MDS/cancer therapy-related AML varied from 0.5 months to 4.9 years.
These patients had received prior chemotherapy with platinum agents
and/or other DNA-damaging agents including radiotherapy.
Discontinue ZEJULA if MDS/AML is
confirmed.
Hematologic adverse reactions (thrombocytopenia,
anemia, neutropenia, and/or pancytopenia) have been reported in
patients receiving ZEJULA. The overall incidence of Grade ≥3
thrombocytopenia, anemia, and neutropenia were reported,
respectively, in 39%, 31%, and 21% of patients receiving ZEJULA in
PRIMA and 29%, 25%, and 20% of patients receiving ZEJULA in NOVA.
Discontinuation due to thrombocytopenia, anemia, and neutropenia
occurred, respectively, in 4%, 2%, and 2% of patients in PRIMA and
3%, 1%, and 2% of patients in NOVA. In
patients who were administered a starting dose of ZEJULA based on
baseline weight or platelet count in PRIMA, Grade ≥3
thrombocytopenia, anemia, and neutropenia were reported,
respectively, in 22%, 23%, and 15% of patients receiving ZEJULA.
Discontinuation due to thrombocytopenia, anemia, and neutropenia
occurred, respectively, in 3%, 3%, and 2% of
patients. Do
not start ZEJULA until patients have recovered from hematological
toxicity caused by prior chemotherapy (≤Grade 1). Monitor
complete blood counts weekly for the first month, monthly for the
next 11 months, and periodically thereafter. If hematological
toxicities do not resolve within 28 days following interruption,
discontinue ZEJULA, and refer the patient to a hematologist for
further investigations.
Hypertension and hypertensive crisis have
been reported in patients receiving ZEJULA. Grade 3-4 hypertension
occurred in 6% of patients receiving ZEJULA vs 1% of patients
receiving placebo in PRIMA, with no reported discontinuations.
Grade 3-4 hypertension occurred in 9% of patients receiving ZEJULA
vs 2% of patients receiving placebo in NOVA, with discontinuation
occurring in <1% of patients. Monitor blood pressure and heart
rate at least weekly for the first two months, then monthly for the
first year, and periodically thereafter during treatment with
ZEJULA. Closely monitor patients with cardiovascular disorders,
especially coronary insufficiency, cardiac arrhythmias, and
hypertension. Manage hypertension with antihypertensive medications
and adjustment of the ZEJULA dose if
necessary.
Posterior reversible encephalopathy syndrome
(PRES) occurred
in 0.1% of 2,165 patients treated with ZEJULA in clinical trials
and has also been described in postmarketing reports. Monitor all
patients for signs and symptoms of PRES, which include seizure,
headache, altered mental status, visual disturbance, or cortical
blindness, with or without associated hypertension. Diagnosis
requires confirmation by brain imaging. If suspected, promptly
discontinue ZEJULA and administer appropriate treatment. The safety
of reinitiating ZEJULA is unknown.
Embryo-fetal toxicity and lactation: Based on its mechanism of action, ZEJULA can
cause fetal harm. Advise females of reproductive potential of the
potential risk to a fetus and to use effective contraception during
treatment and for 6 months after receiving their final dose of
ZEJULA. Because of the potential for serious adverse reactions from
ZEJULA in breastfed infants, advise lactating women to not
breastfeed during treatment with ZEJULA and for 1 month after
receiving the final dose.
Allergic reactions to FD&C Yellow No. 5
(tartrazine): ZEJULA
capsules contain FD&C Yellow No. 5 (tartrazine), which may
cause allergic-type reactions (including bronchial asthma) in
certain susceptible persons. Although the overall incidence in the
general population is low, it is frequently seen in patients who
also have aspirin hypersensitivity.
First-line Maintenance Advanced Ovarian Cancer
Most common adverse reactions (Grades 1-4) in ≥10% of all
patients who received ZEJULA in PRIMA were thrombocytopenia (66%),
anemia (64%), nausea (57%), fatigue (51%), neutropenia (42%),
constipation (40%), musculoskeletal pain (39%), leukopenia (28%),
headache (26%), insomnia (25%), vomiting (22%), dyspnea (22%),
decreased appetite (19%), dizziness (19%), cough (18%),
hypertension (18%), AST/ALT elevation (14%), and acute kidney
injury (12%).
Common lab abnormalities (Grades 1-4) in ≥25% of all patients
who received ZEJULA in PRIMA included: decreased hemoglobin (87%),
decreased platelets (74%), decreased leukocytes (71%), increased
glucose (66%), decreased neutrophils (66%), decreased lymphocytes
(51%), increased alkaline phosphatase (46%), increased creatinine
(40%), decreased magnesium (36%), increased AST (35%) and increased
ALT (29%).
Maintenance Recurrent Ovarian Cancer
Most common adverse reactions (Grades 1-4) in ≥10% of
patients who received ZEJULA in NOVA were nausea (74%),
thrombocytopenia (61%), fatigue/asthenia (57%), anemia (50%),
constipation (40%), vomiting (34%), neutropenia (30%), insomnia
(27%), headache (26%), decreased appetite (25%), nasopharyngitis
(23%), rash (21%), hypertension (20%), dyspnea (20%),
mucositis/stomatitis (20%), dizziness (18%), back pain (18%),
dyspepsia (18%), leukopenia (17%), cough (16%), urinary tract
infection (13%), anxiety (11%), dry mouth (10%), AST/ALT elevation
(10%), dysgeusia (10%), palpitations (10%).
Common lab abnormalities (Grades 1-4) in ≥25% of patients who
received ZEJULA in NOVA included: decrease in hemoglobin (85%),
decrease in platelet count (72%), decrease in white blood cell
count (66%), decrease in absolute neutrophil count (53%), increase
in AST (36%), and increase in ALT (28%).
Please see accompanying US Prescribing Information.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Dan
Smith
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
[i] Worldwide
Cancer Data. World Cancer Research Fund.
https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data.
Updated January 10, 2022. Accessed July 2022.
[ii] Lorusso
D, Mancini M, Di Rocco R, Fontanelli R, Raspagliesi F. The role of
secondary surgery in recurrent ovarian cancer [published online
August 5, 2012]. Int J Surg
Oncol. 2012.
doi:10.1155/2012/613980. Accessed September
2022.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: September
22, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|